What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?

Ming-Yow Hung, Sotirios Tsimikas

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose of review: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and calcific aortic valve stenosis. We review recent studies that highlight Lp(a) in CVD and calcific aortic valve stenosis and propose pathways to clinical registration of Lp(a)-lowering agents. Recent findings: Over the last few years, almost irrefutable evidence has accumulated that Lp(a) is a causal, independent, genetic risk factor for CVD. Most recently, new data have emerged that elevated Lp(a) is causally associated with calcific aortic valve stenosis and the need for aortic valve replacement. Three levels of evidence to support these findings: epidemiological studies, Mendelian randomization studies and genetic association studies. A dedicated Lp(a)-lowering trial has not been performed to date. Emerging Lp(a)-lowering therapies with specific and potent lowering of Lp(a) are in phase II clinical trials and provide a tool to test the hypothesis that lowering Lp(a) plasma levels will lead to clinical benefit. Summary: We provide a rationale for the potential clinical use of Lp(a)-lowering therapies in high-risk patients or patients with established CVD whose major risk factor is elevated Lp(a) levels and propose clinical studies and trials to demonstrate that lowering Lp(a) levels will effectively reduce the risk of calcific aortic valve stenosis and CVD.

Original languageEnglish
Pages (from-to)423-430
Number of pages8
JournalCurrent Opinion in Lipidology
Volume25
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Lipoprotein(a)
Aortic Valve Stenosis
Cardiovascular Diseases
Phase II Clinical Trials
Critical Pathways
Genetic Association Studies
Random Allocation
Aortic Valve
Epidemiologic Studies

Keywords

  • Aortic stenosis
  • Cardiovascular disease
  • Clinical trials
  • Lipoprotein(a)

ASJC Scopus subject areas

  • Cell Biology
  • Genetics
  • Molecular Biology
  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis? / Hung, Ming-Yow; Tsimikas, Sotirios.

In: Current Opinion in Lipidology, Vol. 25, No. 6, 2014, p. 423-430.

Research output: Contribution to journalArticle

@article{2dd2df56ac694570925d00008c163745,
title = "What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?",
abstract = "Purpose of review: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and calcific aortic valve stenosis. We review recent studies that highlight Lp(a) in CVD and calcific aortic valve stenosis and propose pathways to clinical registration of Lp(a)-lowering agents. Recent findings: Over the last few years, almost irrefutable evidence has accumulated that Lp(a) is a causal, independent, genetic risk factor for CVD. Most recently, new data have emerged that elevated Lp(a) is causally associated with calcific aortic valve stenosis and the need for aortic valve replacement. Three levels of evidence to support these findings: epidemiological studies, Mendelian randomization studies and genetic association studies. A dedicated Lp(a)-lowering trial has not been performed to date. Emerging Lp(a)-lowering therapies with specific and potent lowering of Lp(a) are in phase II clinical trials and provide a tool to test the hypothesis that lowering Lp(a) plasma levels will lead to clinical benefit. Summary: We provide a rationale for the potential clinical use of Lp(a)-lowering therapies in high-risk patients or patients with established CVD whose major risk factor is elevated Lp(a) levels and propose clinical studies and trials to demonstrate that lowering Lp(a) levels will effectively reduce the risk of calcific aortic valve stenosis and CVD.",
keywords = "Aortic stenosis, Cardiovascular disease, Clinical trials, Lipoprotein(a)",
author = "Ming-Yow Hung and Sotirios Tsimikas",
year = "2014",
doi = "10.1097/MOL.0000000000000131",
language = "English",
volume = "25",
pages = "423--430",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?

AU - Hung, Ming-Yow

AU - Tsimikas, Sotirios

PY - 2014

Y1 - 2014

N2 - Purpose of review: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and calcific aortic valve stenosis. We review recent studies that highlight Lp(a) in CVD and calcific aortic valve stenosis and propose pathways to clinical registration of Lp(a)-lowering agents. Recent findings: Over the last few years, almost irrefutable evidence has accumulated that Lp(a) is a causal, independent, genetic risk factor for CVD. Most recently, new data have emerged that elevated Lp(a) is causally associated with calcific aortic valve stenosis and the need for aortic valve replacement. Three levels of evidence to support these findings: epidemiological studies, Mendelian randomization studies and genetic association studies. A dedicated Lp(a)-lowering trial has not been performed to date. Emerging Lp(a)-lowering therapies with specific and potent lowering of Lp(a) are in phase II clinical trials and provide a tool to test the hypothesis that lowering Lp(a) plasma levels will lead to clinical benefit. Summary: We provide a rationale for the potential clinical use of Lp(a)-lowering therapies in high-risk patients or patients with established CVD whose major risk factor is elevated Lp(a) levels and propose clinical studies and trials to demonstrate that lowering Lp(a) levels will effectively reduce the risk of calcific aortic valve stenosis and CVD.

AB - Purpose of review: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD) and calcific aortic valve stenosis. We review recent studies that highlight Lp(a) in CVD and calcific aortic valve stenosis and propose pathways to clinical registration of Lp(a)-lowering agents. Recent findings: Over the last few years, almost irrefutable evidence has accumulated that Lp(a) is a causal, independent, genetic risk factor for CVD. Most recently, new data have emerged that elevated Lp(a) is causally associated with calcific aortic valve stenosis and the need for aortic valve replacement. Three levels of evidence to support these findings: epidemiological studies, Mendelian randomization studies and genetic association studies. A dedicated Lp(a)-lowering trial has not been performed to date. Emerging Lp(a)-lowering therapies with specific and potent lowering of Lp(a) are in phase II clinical trials and provide a tool to test the hypothesis that lowering Lp(a) plasma levels will lead to clinical benefit. Summary: We provide a rationale for the potential clinical use of Lp(a)-lowering therapies in high-risk patients or patients with established CVD whose major risk factor is elevated Lp(a) levels and propose clinical studies and trials to demonstrate that lowering Lp(a) levels will effectively reduce the risk of calcific aortic valve stenosis and CVD.

KW - Aortic stenosis

KW - Cardiovascular disease

KW - Clinical trials

KW - Lipoprotein(a)

UR - http://www.scopus.com/inward/record.url?scp=84926451410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926451410&partnerID=8YFLogxK

U2 - 10.1097/MOL.0000000000000131

DO - 10.1097/MOL.0000000000000131

M3 - Article

C2 - 25340480

AN - SCOPUS:84926451410

VL - 25

SP - 423

EP - 430

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 6

ER -